Journal ArticleDOI
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study
Henryk Barthel,Hermann-Josef Gertz,Stefan Dresel,Oliver Peters,Peter Bartenstein,Katharina Buerger,Florian Hiemeyer,Sabine M Wittemer-Rump,John Seibyl,Cornelia Reininger,Osama Sabri +10 more
TLDR
The diagnostic efficacy of the scans was established in differentiating between patients with probable disease and age-matched healthy controls on the basis of neocortical tracer uptake pattern 90-110 min post-injection and the sensitivity and specificity of florbetaben (¹⁸F) PET was assessed.Abstract:
Summary Background Imaging with amyloid-β PET can potentially aid the early and accurate diagnosis of Alzheimer's disease. Florbetaben ( 18 F) is a promising 18 F-labelled amyloid-β-targeted PET tracer in clinical development. We aimed to assess the sensitivity and specificity of florbetaben ( 18 F) PET in discriminating between patients with probable Alzheimer's disease and elderly healthy controls. Methods We did a multicentre, open-label, non-randomised phase 2 study in 18 centres in Australia, Germany, Switzerland, and the USA. Imaging with florbetaben ( 18 F) PET was done on patients with probable Alzheimer's disease (age 55 years or older, mini-mental state examination [MMSE] score=18–26, clinical dementia rating [CDR]=0·5–2·0) and age-matched healthy controls (MMSE ≥28, CDR=0). Our primary objective was to establish the diagnostic efficacy of the scans in differentiating between patients with probable disease and age-matched healthy controls on the basis of neocortical tracer uptake pattern 90–110 min post-injection. PET images were assessed visually by three readers masked to the clinical diagnosis and all other clinical findings, and quantitatively by use of pre-established brain volumes of interest to obtain standard uptake value ratios (SUVRs), taking the cerebellar cortex as the reference region. This study is registered with ClinicalTrials.gov, number NCT00750282. Findings 81 participants with probable Alzheimer's disease and 69 healthy controls were assessed. Independent visual assessment of the PET scans showed a sensitivity of 80% (95% CI 71–89) and a specificity of 91% (84–98) for discriminating participants with Alzheimer's disease from healthy controls. The SUVRs in all neocortical grey-matter regions in participants with Alzheimer's disease were significantly higher (p r −0·27 to −0·33, p≤0·021). APOE ɛ4 was more common in participants with positive PET images compared with those with negative scans (65% vs 22% [p=0·027] in patients with Alzheimer's disease; 50% vs 16% [p=0·074] in healthy controls). No safety concerns were noted. Interpretation We provide verification of the efficacy, safety, and biological relevance of florbetaben ( 18 F) amyloid-β PET and suggest its potential as a visual adjunct in the diagnostic algorithm of dementia. Funding Bayer Schering Pharma AG.read more
Citations
More filters
Journal ArticleDOI
Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Xueqi Chen,Xueqi Chen,Yun Zhou,Yun Zhou,Rongfu Wang,Haoyin Cao,Savina Reid,Rui Gao,Dong Han,Alzheimer’s Disease Neuroimaging Initiative +9 more
TL;DR: Quantitative FDG and 11C-PiB PET with clinical cognitive assessments significantly improved accuracy in the predication of Alzheimer’s disease progression.
Journal ArticleDOI
Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
Isadora Lopes Alves,Lyduine E. Collij,Daniele Altomare,Giovanni B. Frisoni,Laure Saint-Aubert,Pierre Payoux,Miia Kivipelto,Frank Jessen,Alexander Drzezga,Annebet E. Leeuwis,Alle Meije Wink,Pieter Jelle Visser,Bart N.M. van Berckel,Philip Scheltens,Katherine R. Gray,Robin Wolz,Andrew W. Stephens,Rossella Gismondi,Christopher Buckely,Juan Domingo Gispert,Mark E. Schmidt,Lisa Ford,Craig W. Ritchie,Gill Farrar,Frederik Barkhof,José Luis Molinuevo +25 more
TL;DR: The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Prognostic and Natural History Study (PNHS) adds (semi‐)quantitative amyloid PET imaging to several European parent cohorts (PCs) to predict AD‐related progression as well as address methodological challenges in amyloids PET.
Journal ArticleDOI
A 18F-labeled BF-227 derivative as a potential radioligand for imaging dense amyloid plaques by positron emission tomography.
Shozo Furumoto,Nobuyuki Okamura,Katsutoshi Furukawa,Manabu Tashiro,Yoichi Ishikawa,Kentaro Sugi,Naoki Tomita,Masaaki Waragai,Ryuichi Harada,Tetsuro Tago,Ren Iwata,Kazuhiko Yanai,Hiroyuki Arai,Yukitsuka Kudo +13 more
TL;DR: Evaluated 18F-labeled ethenyl-benzoxazole derivatives showed high binding affinity for synthetic Aβ fibrils, preferential binding to dense cored plaques in brain sections, and excellent brain uptake and rapid clearance in mice, suggesting [18F]FACT is a promising agent for imaging dense Aβ plaque in AD.
Journal ArticleDOI
99mTc-Labeled 2-Arylbenzothiazoles: Aβ Imaging Probes with Favorable Brain Pharmacokinetics for Single-Photon Emission Computed Tomography
Xiaoyang Zhang,Pingrong Yu,Yanping Yang,Yaqin Hou,Cheng Peng,Zhigang Liang,Jing Lu,Baian Chen,Jiapei Dai,Boli Liu,Mengchao Cui +10 more
TL;DR: The results indicate that [99mTc]14b could be utilized as a SPECT imaging probe for Aβ plaques and showed that it penetrated the brains of rhesus monkeys.
Journal ArticleDOI
Brain [18F]FDDNP Binding and Glucose Metabolism in Advanced Elderly Healthy Subjects and Alzheimer's Disease Patients
Clovis Tauber,Emilie Beaufils,Caroline Hommet,Maria Joao Ribeiro,Johnny Vercouillie,Emilie Vierron,Emilie Vierron,Karl Mondon,Jean-Philippe Cottier,Valérie Gissot,Denis Guilloteau,Denis Guilloteau,Vincent Camus +12 more
TL;DR: Imaging Aβ load and NFT with [18F]FDDNP can distinguish AD patients from HCs in an advanced elderly population, and seems to be less sensitive to the brain changes observed with normal aging, but more sensitive to cognitive decline in advanced elderly AD patients.
References
More filters
Journal ArticleDOI
“Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician
Marshal F. Folstein,Marshal F. Folstein,Susan E B Folstein,Susan E B Folstein,Paul R. McHugh,Paul R. McHugh +5 more
TL;DR: A simplified, scored form of the cognitive mental status examination, the “Mini-Mental State” (MMS) which includes eleven questions, requires only 5-10 min to administer, and is therefore practical to use serially and routinely.
A practical method for grading the cognitive state of patients for the clinician
TL;DR: The Mini-Mental State (MMS) as mentioned in this paper is a simplified version of the standard WAIS with eleven questions and requires only 5-10 min to administer, and is therefore practical to use serially and routinely.
Journal ArticleDOI
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.
TL;DR: A nonparametric approach to the analysis of areas under correlated ROC curves is presented, by using the theory on generalized U-statistics to generate an estimated covariance matrix.
Journal ArticleDOI
Neuropathological stageing of Alzheimer-related changes.
Heiko Braak,Eva Braak +1 more
TL;DR: The investigation showed that recognition of the six stages required qualitative evaluation of only a few key preparations, permitting the differentiation of six stages.
Journal ArticleDOI
Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain
Nathalie Tzourio-Mazoyer,B. Landeau,D. Papathanassiou,Fabrice Crivello,Octave Etard,Nicolas Delcroix,Bernard Mazoyer,Marc Joliot +7 more
TL;DR: An anatomical parcellation of the spatially normalized single-subject high-resolution T1 volume provided by the Montreal Neurological Institute was performed and it is believed that this tool is an improvement for the macroscopical labeling of activated area compared to labeling assessed using the Talairach atlas brain.
Related Papers (5)
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
William E. Klunk,Henry Engler,Agneta Nordberg,Yanming Wang,G. Blomqvist,Daniel P. Holt,Mats Bergström,Irina Savitcheva,Guo Feng Huang,Sergio Estrada,Birgitta Ausén,Manik L. Debnath,Julien Barletta,Julie C. Price,Johan Sandell,Brian J. Lopresti,Anders Wall,Pernilla Koivisto,Gunnar Antoni,Chester A. Mathis,Bengt Långström +20 more
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann,Guy M. McKhann,David S. Knopman,Howard Chertkow,Bradley T. Hyman,Clifford R. Jack,Claudia H. Kawas,William E. Klunk,Walter J. Koroshetz,Jennifer J. Manly,Richard Mayeux,Richard C. Mohs,John C. Morris,Martin N. Rossor,Philip Scheltens,Maria C. Carrillo,Bill Thies,Sandra Weintraub,Creighton H. Phelps +18 more
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Christopher M. Clark,Julie A. Schneider,Barry J. Bedell,Thomas G. Beach,Warren B. Bilker,Mark A. Mintun,Michael J. Pontecorvo,Franz Hefti,Alan Carpenter,Matthew Flitter,Michael J. Krautkramer,Hank F. Kung,R. Edward Coleman,P. Murali Doraiswamy,Adam S. Fleisher,Marwan N. Sabbagh,Carl H. Sadowsky,Eric M. Reiman,Simone P. Zehntner,Daniel Skovronsky +19 more
Imaging beta-amyloid burden in aging and dementia.
Christopher C. Rowe,Steven Ng,Uwe Ackermann,Sylvia J. Gong,Kerryn E. Pike,Gregory Raymond Savage,Tiffany F. Cowie,Kerryn L Dickinson,Paul Maruff,David Darby,Clare Smith,Michael Woodward,John Merory,Henri Tochon-Danguy,Graeme O'Keefe,William E. Klunk,Chett A Mathis,Julie C. Price,Colin L. Masters,Colin L. Masters,Victor L. Villemagne,Victor L. Villemagne +21 more